**Revenue distribution by sectors:**
1. Diagnostic products: approx. 60%
2. Biotechnology services: approx. 25%
3. Research and development: approx. 15%

**Top 3 markets and their percentage shares:**
1. China: approx. 70%
2. USA: approx. 15%
3. Europe: approx. 10%

Daan Gene Co., Ltd. generates the majority of its revenue from the sale of diagnostic products widely used in medical diagnostics. The Chinese market is the largest and most important for the company, attributed to its strong local presence and high demand for medical diagnostic solutions.

In the USA and Europe, the company also holds significant market shares, strengthened by strategic partnerships and the export of diagnostic solutions.

**Production Sites:**
- Headquarters and main production facility: Guangzhou, China
- Other production facilities: In various regions of China

Daan Gene Co., Ltd. is a leading company in the field of biotechnological research and production. The headquarters and primary production facility are located in Guangzhou, China. In addition, the company operates several production facilities in various regions of China to meet demand both domestically and internationally. This strategic distribution enables Daan Gene to efficiently respond to market demands and optimize logistics.

**Revenue Growth:** 10.5% (2025)

**Research & Development:** 8% of revenue (2025)

Daan Gene Co., Ltd. pursues a strategy that is strongly focused on innovation and research & development (R&D). The company continuously invests in R&D to expand and enhance its product range in the field of molecular diagnostics. This is reflected in allocating 8% of revenue to R&D activities in 2025.

Another focus is on international expansion. In recent years, Daan Gene Co., Ltd. has strengthened its presence in international markets, especially in Asia and Europe, to capitalize on the growing demand for diagnostic solutions.

Additionally, the company is leveraging strategic partnerships and collaborations to expand its technological capabilities and tap into new market segments. This strategy is intended to further promote revenue growth and strengthen its competitive position.

**Main Imported Raw Materials:** Chemicals, reagents, laboratory equipment

**Countries of Origin:** USA, Germany, Japan

Daan Gene Co., Ltd. is a company specializing in biotechnological products and services. For the production of their diagnostic kits and biotechnological products, the company mainly imports special chemicals and reagents. These materials are essential for the development and production of high-quality diagnostic tests.

The USA, Germany, and Japan are leading countries in the production of high-quality biotechnological materials and laboratory equipment. Therefore, Daan Gene sources a large portion of its imported raw materials from these countries to ensure that their products meet international standards and remain competitive.

**Market Share:** Estimated 20% in the Chinese diagnostics market (2026)

**Research & Development:** Invested 8% of revenue (2025)

Daan Gene Co., Ltd. has a significant competitive advantage in the field of molecular diagnostics, especially in China. The company benefits from a strong market share and a solid position in the domestic market.

A key factor for the competitive advantage is the continuous investment in research and development, which enables the company to bring innovative products to the market. These investments strengthen the product pipeline and improve competitiveness.

Furthermore, Daan Gene has established strategic partnerships and collaborations that facilitate access to new technologies and markets. This helps to further solidify the market position and increase growth potential.

**Institutional Investor Share:** Estimated at 25-30% (2026)

**Insider Purchases/Sales:** No specific data available (2026)

The institutional investor share in Daan Gene Co., Ltd. is estimated to be between 25 and 30 percent. This is typical for companies of this size and industry, as institutional investors often invest in high-growth companies to benefit from future returns.

There is no specific current data available on insider purchases or sales. However, such transactions can vary significantly and are often dependent on strategic decisions or personal circumstances of the insiders. It would be advisable to consult the latest stock market announcements or financial reports of the company for more detailed information.

**Market share of Daan Gene Co., Ltd.:** Estimated 8% (2026)

**Top competitors and market shares:**
1. BGI Genomics Co., Ltd. - 15%
2. WuXi AppTec Co., Ltd. - 12%
3. KingMed Diagnostics Group Co., Ltd. - 10%
4. Zhejiang Dian Diagnostics Co., Ltd. - 9%
5. Daan Gene Co., Ltd. - 8%
6. Berry Genomics Co., Ltd. - 7%
7. Amoy Diagnostics Co., Ltd. - 6%
8. Hybribio Limited - 5%
9. Beijing Genomics Institute - 4%
10. GeneDx Holdings - 3%

**Moat of Daan Gene Co., Ltd.:**

Daan Gene Co., Ltd. has a moderate moat, mainly attributed to its long-standing experience in the field of molecular diagnostics and its established relationships in the healthcare sector. The company has built a reputation through continuous innovations and the development of new diagnostic tests.

In comparison to its competitors, BGI Genomics has a stronger moat based on its extensive database and leading position in genomics research. WuXi AppTec benefits from a wide range of services and a global presence, which also provides a significant advantage.

Daan Gene must continue to focus on innovations and strategic partnerships to strengthen its moat and compete with the larger players in the industry.

**Revenue Growth:** 10% (2025)
**R&D Expenses:** 15% of revenue (2025)
**Market Share in China:** 20% in molecular diagnostics sector (2025)

Daan Gene Co., Ltd. achieved a revenue growth of 10% in 2025, driven by strong demand for their molecular diagnostic products. The company is heavily investing in research and development, with 15% of revenue allocated to this area. This indicates a strategic focus on innovation and long-term growth.

With a 20% market share in the molecular diagnostics sector in China, Daan Gene is well positioned to benefit from the growing demand for healthcare solutions. The strong market position and continuous investments in R&D could further strengthen the company in the coming years.

Overall, Daan Gene demonstrates a solid growth strategy and a strong market presence, pointing towards positive long-term prospects. However, investors should also keep an eye on external factors such as regulatory changes and competition.

**Dividend Yield:** 2.5% (2025)
**Dividend History:** Consistent payout over the last 5 years

Daan Gene Co., Ltd. has regularly distributed dividends in recent years. The dividend yield was around 2.5% in 2025, which can be considered moderate compared to other companies in the industry.

The reliability of dividend payments is underscored by the continuous payout over the last five years. This suggests that the company has a stable financial foundation and is committed to providing its shareholders with regular returns. Analysts expect that Daan Gene Co., Ltd. will continue to pursue a similar dividend policy in the coming years, unless significant negative economic developments occur.